Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.
Who Can Benefit from Spravato?
Treatment-Resistant Depression (TRD)
Treatment-resistant depression is depression that does
not improve with two or more antidepressants tried at
adequate dosages and duration.
Major Depressive Disorder with Suicidal Ideations
If you have major depressive disorder and have
expressed suicidal thoughts or behaviors, Spravato®
nasal spray may be an appropriate next step in treatment.
Getting Started with Spravato® Treatment
- Nasal administration of Spravato® (under supervision)
- 2 hours of monitoring in a comfortable, private setting
- Ongoing support from our medical team
As your symptoms improve, treatments are gradually reduced:
- Week 5–8: Once weekly
- After Week 8: Every 1–2 weeks, based on your response
- Your treatment plan is customized as you progress.
How To Get Started
- Nasal administration of Spravato® (under supervision)
- 2 hours of monitoring in a comfortable, private setting
- Ongoing support from our medical team
- Week 5–8: Once weekly
- After Week 8: Every 1–2 weeks, based on your response Your treatment plan is customized as you progress.
Patient Testimonials
FAQ
Yes, Spravato (esketamine nasal spray) is generally covered by most insurance plans in the U.S., including Medicare and private insurers. However, coverage specifics can vary based on your insurance provider, plan type, and individual circumstances.
Yes, Spravato (esketamine) is now FDA-approved as a standalone treatment for adults with treatment-resistant depression (TRD).
Some of the common side effects of Spravato are dizziness, nausea, headache and can increase blood pressure.
Patients are not to eat for at least 2 hours before your treatment and are not to drink at least 30 minutes before your treatment.
